Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637
This examiner grants 41% of resolved cases
Julio Washington Gomez Rodriguez examines cases in Tech Center 1600 and Art Unit 1637. There are 29 resolved cases in the data. The allowance rate is 41.4 percent. This percentage indicates the frequency of grants within this docket for applications reaching a final resolution, providing a baseline for the probability of success.
The interview lift is 58.4 percent. This figure is very large when compared to the 41.4 percent allowance rate, suggesting that interviews are an exceptionally effective tool for improving outcomes. Practitioners should prioritize direct engagement to resolve outstanding issues and clarify technical disagreements, as supported by the 29 resolved cases recorded in this docket.
The median time to allowance is 1380 days. This duration represents the typical prosecution cycle for granted patents. While the data is based on 29 resolved cases, the 58.4 percent interview lift provides a clear strategic recommendation for applicants seeking to improve their chances of a patent grant, providing a reliable basis for strategy and expectation management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18598746 | USE OF MECP2 AS BIOMARKER FOR DEPRESSION DIAGNOSIS AND DEPRESSION TREATMENT TARGET | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18594910 | Method of Treatment for Auditory Dysfunction | Non-Final OA | University of South Florida |
| 18567629 | RECOMBINANT ADENO-ASSOCIATED VIRUSES FOR LESCH-NYHAN DISORDERS AND USES THEREOF | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18549856 | METHOD FOR THE PRODUCTION OF SEAMLESS DNA VECTORS | Non-Final OA | Nanyang Technological University |
| 18696034 | Use of Inhibitors to Increase Efficiency of Crispr/CAS Insertions | Non-Final OA | AstraZeneca AB |
| 18597260 | CLASS II, TYPE V CRISPR SYSTEMS | Non-Final OA | Metagenomi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy